1H-imidazole-4(5)-carboxylic acid phenylmethyl ester | 1208114-68-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1H-imidazole-4(5)-carboxylic acid phenylmethyl ester
• 英文别名: benzyl 1H-imidazole-4-carboxylate；1H-imidazole-4-carboxylic acid phenylmethyl ester；benzyl 1H-imidazole-5-carboxylate
• CAS: 1208114-68-4
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: WDRWAKUUCWDCBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-溴丁酸乙酯 、 1H-imidazole-4(5)-carboxylic acid phenylmethyl ester 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以348 mg的产率得到benzyl 1-(4-ethoxy-4-oxobutan-2-yl)-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  AZABENZIMIDAZOLE COMPOUND AND MEDICINE

  摘要：

  本发明的目的是提供具有M3 PAM活性的化合物。本发明的示例包括以下式[1]所表示的氮杂苯并咪唑化合物及其药学上可接受的盐。本发明的化合物具有M3 PAM活性。此外，由于本发明的化合物具有M3 PAM活性，因此本发明的化合物可用作预防剂或治疗剂，用于治疗下行性膀胱、低张性膀胱、无收缩性膀胱、膀胱下活动障碍和神经源性膀胱的排尿障碍和尿液收集障碍。

  公开号：

  EP4059933A1
• 作为产物：
  描述：

  溴甲苯 、 1H-咪唑-4-甲酸 在 水 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以60%的产率得到1H-imidazole-4(5)-carboxylic acid phenylmethyl ester
  参考文献：
  名称：

  新的2-吡咯烷酮衍生物的合成，计算机对接实验和抗炎活性的研究

  摘要：

  设计，合成并测试了新型的2-吡咯烷酮衍生物的抗氧化和抗炎活性。评价化合物对LOX的抑制活性。还测试了其中最有效的14d [IC 50 0.08（±0.005）mM]和14e [IC 50 0.0705（±0.003）mM]。化合物14d诱导了对大鼠爪水肿的等电位抑制，这与常用标准吲哚美辛（47％）产生的效果非常接近。化合物14e的LOX抑制活性脂质过氧化抑制百分比的值平行进行，这意味着该LOX抑制活性由脂质过氧化抑制支持。通过计算机对接实验探索了控制其生物活性的分子特征。结果表明，酸性部分必须在LOX酶的活性位点以一定的距离和方向放置，以便有效地发挥抑制活性。另外，2-吡咯烷酮模板对新化合物的抑制特性有显着贡献。

  DOI：

  10.1016/j.bmc.2011.03.044

文献信息

• [EN] TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES TÉTRASUBSTITUÉS ET LEUR UTILISATION COMME MODULATEURS DE MDM2 ET/OU MDM4
  申请人：NOVARTIS AG

  公开号：WO2011023677A1

  公开（公告）日：2011-03-03

  The invention relates to tetra-substituted heteroarylic compounds of the formula (I) wherein X1, X3 and X4 are independently C or N, Y is C-H, N-H or N, wherein the total number of nitrogen atoms represented by X1, X3, X4 and Y is 1 or 2; rings A and B are independently selected from phenyl or pyridyl; R1, R4, R', R", n and m are as defined herein. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

  该发明涉及公式（I）的四取代杂芳基化合物，其中X1、X3和X4独立地为C或N，Y为C-H、N-H或N，其中由X1、X3、X4和Y表示的氮原子的总数为1或2；环A和环B独立地选自苯基或吡啶基；R1、R4、R'、R"、n和m如本文所定义。这些化合物适用于治疗由MDM2和/或MDM4的活性或其变体介导的疾病或疾病。
• Synthesis of New Optically Active 2-Pyrrolidinones
  作者：Panagiota Moutevelis-Minakakis、Eleni Papavassilopoulou、Thomas Mavromoustakos

  DOI：10.3390/molecules18010050

  日期：——

  A new class of optically active 2-pyrrolidinones was synthesized, starting from S-pyroglutamic acid, a well known natural chiral synthon. The synthetic design followed led to the insertion of various substituents at positions 1 and 5 of the 2-pyrrolidinone ring, including the imidazole moiety. Some of them possess two or three stereogenic centers, the configuration of which was retained under the mild

  合成了一类新的光学活性 2-吡咯烷酮，从 S-焦谷氨酸开始，这是一种众所周知的天然手性合成子。随后的合成设计导致在 2-吡咯烷酮环的 1 和 5 位插入各种取代基，包括咪唑部分。其中一些具有两个或三个立体中心，其构型在所使用的温和条件下得以保留。新化合物还带有一个咪唑部分，与 2-吡咯烷酮模板一起，可能证明对几种生物过程至关重要。
• [EN] GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RECEPTEURS DE LA GASTRINE ET DE LA CHOLECYSTOKININE
  申请人：BLACK JAMES FOUNDATION

  公开号：WO2000027823A1

  公开（公告）日：2000-05-18

  Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)- =CH-, -S- or -O-. n is from 1 to 4; R1 is H or C¿1? to C15 hydrocarbyl R?2¿ is selected from H, Me, Et, Pr and OH, R¿3? is selected from H, Me, Et and Pr; or (when n is greater than 1) each R?3¿ is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C¿3? to C6 carbocylic ring, or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl Z is -(NR7)a-CO-(NR8)b- (wherein a is 0 or 1, b is 0 or 1, -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH¿2?-CH2-, -CH=CH-, -CH2-NR?8¿- or a bond; Q is -R9V, or (II), (wherein R9 is -CH¿2?-; -CH2-CH2-; or (III), R?9 and R8¿, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is -CO-NH-SO¿2?-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R?10¿U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO¿3?H; and R?10¿ is a bond; C¿1? to C6 hydrocarbylene, -O-(C1 to C3 alkylene)-; -SO2NR?11-CHR12¿-; -CO-NR?11-CHR12¿-, or -NH-(CO)¿c?-CH2-, c being 0 or 1).

  式(I)化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为=N-，-N（R5）-，=CH-，-S-或-O-。n为1至4；R1为H或C1至C15的烃基；R2从H，Me，Et，Pr和OH中选择，R3从H，Me，Et和Pr中选择；或（当n大于1时）每个R3独立地从H，Me，Et和Pr中选择，或相邻碳原子上的两个R3基团连接形成C3至C6的环烷基，或R2和R3在同一碳原子上共同表示一个=O基团；R4为C1至C15的烃基，Z为-(NR7)a-CO-(NR8)b-（其中a为0或1，b为0或1，-CO-NR7-CH2-CO-NR8-，-CO-O-，-CH2-CH2-，-CH=CH-，-CH2-NR8-或键；Q为-R9V，或（II），（其中R9为-CH2-；-CH2-CH2-；或（III），R9和R8，连同R8所连接的氮原子，形成被V取代的哌嗪或吡咯烷环；V为-CO-NH-SO2-Ph，-SO2-NH-CO-Ph，-CH2OH，或式-R10U的基团（其中U为-COOH，四唑基，-CONHOH-或-SO3H；R10为键；C1至C6的烃亚基，-O-（C1至C3的烷基）-；-SO2NR11-CHR12-；-CO-NR11-CHR12-，或-NH-（CO）c-CH2-，其中c为0或1）。
• Synthesis of modified diaminopurines and their incorporation into oligomers
  申请人：DAKO A/S

  公开号：EP1085020A1

  公开（公告）日：2001-03-21

  Protected diaminopurines can be used in the synthesis of nucleic acid binding compounds containing diaminepurine in place of other nucleobases. A method for the synthesis of protected diaminopurines is disclosed which is convenient for incorporating modified diaminopurines into monomers or into oligomers for the preparation of nucleic acid binding compounds.

  受保护的二氨基嘌呤可用于合成含有二氨基嘌呤而不是其他核碱基的核酸结合化合物。本发明公开了一种合成受保护二氨基嘌呤的方法，该方法便于将改性二氨基嘌呤加入单体或低聚物中，以制备核酸结合化合物。
• Synthesis and Testing of Heterocyclic Analogs of Diaminopimelic Acid (DAP) as Inhibitors of DAP Dehydrogenase and DAP Epimerase
  作者：Shaun D. Abbott、Patricia Lane-Bell、Kanwar P. S. Sidhu、John C. Vederas

  DOI：10.1021/ja00094a004

  日期：1994.7

  Substrate analogues were synthesized and examined as inhibitors of diaminopimelic acid (DAP) dehydrogenase from Bacillus sphaericus and of DAP epimerase from Escherichia coli. These enzymes produce meso-DAP (3) (a precursor for L-lysine and for peptidoglycan) from L-tetrahydrodipicolinic acid (1) and LL-DAP (2), respectively. The epimerase was purified by an improved procedure and confirmed to require both carboxyl and both amino groups for substrate recognition using deuterium-exchange experiments with DAP isomers, L-lysine, D-lysine, L-alpha-aminopimelate, and racemic alpha-aminopimelate. An imidazole analogue of DAP, (2S)-2-amino-3-(4-carboxyimidazol-1-yl)propanoic acid (4), was synthesized by condensation of benzyl imidazole-4-carboxylate (8) with N-benzyloxycarbonyl(Cbz)-L-serine beta-lactone (9) (product structure confirmed by X-ray analysis) followed by hydrogenolytic deprotection. Two other analogues, (2S,5'R)-2-amino-3-(3-carboxy-2-isoxazolin-5-yl)propanoic acid (5) and its 5'S diastereomer 6, were prepared by condensation of methyl N-Cbz-L-allylglycinate (13) with methyl chlorooximidoacetate (14) followed by separation of isomers and deprotection with NaOH and Me(3)SiCl/NaI. Similar condensation of ethyl chlorooximidoacetate with ethylene and of 14 with ethyl acrylate generated isoxazolines, which were saponified to 2-isoxazoline-3-carboxylic acid (25) and 2-isoxazoline-3,5-dicarboxylic acid (26), respectively. None of the compounds show significant inhibition of DAP epimerase or DAP dehydrogenase with the exception of 6, which is a potent and specific inhibitor of DAP dehydrogenase. At pH 7.5 or 7.8, compound 6 shows competitive inhibition (K-i = 4.2 mu M) with tetrahydrodipicolinic acid (1) for the forward reaction and noncompetitive inhibition (K-i = 23 mu M) with meso-DAP (3) for the reverse process. Preliminary tests for antimicrobial activity demonstrate that 6 inhibits the growth of B. sphaericus, which relies exclusively on DAP dehydrogenase to produce 3.